Publication:
Multicenter evaluation of ceftazidime-avibactam use in carbapenem-resistant klebsiella pneumoniae bloodstream infections in oxa-48 endemic regions

dc.contributor.authorMert, Ali
dc.contributor.authorDerin, Okan
dc.contributor.authorDumlu, Ridvan
dc.contributor.authorGündeş, Sibel
dc.contributor.authorZengin, Rehile
dc.contributor.authorKocagöz, Sesin
dc.contributor.authorGundoğdu, Yasemin
dc.contributor.authorKöksal, Iftihar
dc.contributor.authorYalçın, Demet
dc.contributor.authorÜstün, Cemal
dc.contributor.authorKapmaz, Mahir
dc.contributor.authorGörenek, Levent
dc.contributor.authorKarahangil, Kadriye
dc.contributor.authorCan, Füsun
dc.contributor.authorErgönül, Önder
dc.contributor.buuauthorAKALIN, EMİN HALİS
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentEnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Ana Bilim Dalı.
dc.contributor.researcheridKWG-0138-2024
dc.date.accessioned2025-02-18T05:53:58Z
dc.date.available2025-02-18T05:53:58Z
dc.date.issued2024-11-01
dc.description.abstractData in the literature on the use of ceftazidime-avibactam (CAZ-AVI) in carbapenem-resistant Klebsiella pneumoniae bloodstream infections (CRKP-BSIs) are limited especially in OXA-48 (Oxacillinase-48) predominant regions. Our study aimed to evaluate the effect of CAZ-AVI use on outcomes in CRKP-BSIs in Turkey, where OXA-48 is endemic. A multicenter retrospective observational study was conducted between January 2017 and September 2021. The effects of clinical and treatment characteristics on 30-day mortality and relapse in CRKP-BSIs were analyzed. Predictors of outcomes were detected using a Cox regression model. The study enrolled 106 adults with CAZ-AVI-sensitive CRKP-BSIs who received CAZ-AVI for at least 72 h. Patients who received CAZ-AVI as initial therapy had lower mortality rates when compared to those who switched from last resort regimens [14.3% (n = 3/21) vs. 37.7% (n = 32/85), p = 0.04]. In multivariate analysis, older age and severe neutropenia were detected to be associated with higher mortality, significantly. Initiation of CAZ-AVI on the day of blood culture was obtained, was found to be significantly associated with lower mortality (HR: 0.25, CI: 0.07-0.84, p = 0.025). CAZ-AVI monotherapy is an important treatment option for CRKP-BSIs in OXA-48 endemic areas. Early initiation of CAZ-AVI should be preferred rather than switching from a last-resort regimen as it profoundly improves the survival rates.
dc.identifier.doi10.1038/s41598-024-77259-z
dc.identifier.issn2045-2322
dc.identifier.issue1
dc.identifier.scopus2-s2.0-85208291818
dc.identifier.urihttps://doi.org/10.1038/s41598-024-77259-z
dc.identifier.urihttps://hdl.handle.net/11452/50491
dc.identifier.volume14
dc.identifier.wos001346703300034
dc.indexed.wosWOS.SCI
dc.language.isoen
dc.publisherNature Portfolio
dc.relation.journalScientific Reports
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectBloodstream infections
dc.subjectCarbapenem-resistant klebsiella pneumoniae
dc.subjectCeftazidime-avibactam
dc.subjectOxa-48
dc.subjectOxa-48 endemic area
dc.subjectScience & technology
dc.subjectMultidisciplinary sciences
dc.titleMulticenter evaluation of ceftazidime-avibactam use in carbapenem-resistant klebsiella pneumoniae bloodstream infections in oxa-48 endemic regions
dc.typeArticle
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Ana Bilim Dalı.
local.indexed.atWOS
local.indexed.atScopus
relation.isAuthorOfPublication4fb46529-3295-4383-97b1-7c494ff32c24
relation.isAuthorOfPublication.latestForDiscovery4fb46529-3295-4383-97b1-7c494ff32c24

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Akalin_vd_2024.pdf
Size:
1.42 MB
Format:
Adobe Portable Document Format